Skip to main content
Figure 5 | Breast Cancer Research

Figure 5

From: Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer

Figure 5

Inhibition of PDGFRβ and Abl with nilotinib reduces ER protein stability. Wt MCF 7 and LTED cells were treated with nilotinib (2 µM) ± E2 for 24 hours. Cell monolayers were subsequently harvested and whole cell extracts probed for the proteins indicated. Data shown are representative of three independent experiments. Abl, Abelson tyrosine kinase; E2, estradiol; LTED, long term estrogen deprived; Wt, wild type.

Back to article page
\